Dascena, founded in 2014, is driving innovation at the intersection of Big Data, Biotechnology, and Health Care. With a focus on early disease intervention, the company is pioneering advanced machine learning algorithms that leverage healthcare patient data to enhance patient care outcomes.
The company addresses critical unmet needs in healthcare by developing solutions for clinical decision support, point of care diagnostics, and biopharma companion diagnostics. Their technologies aim to optimize care delivery and play a pivotal role in improving diagnostics and, ultimately, saving lives.
The latest financial backing for Dascena came in the form of a grant investment from the National Institutes of Health on 29 March 2022, highlighting the confidence placed in their strategic direction and innovation capabilities. This support underscores their potential to make significant inroads in the healthcare industry, presenting a compelling opportunity for future investors seeking impactful ventures.
